Showing 7221-7230 of 9737 results for "".
- Xeomin Injunction Stands; Another Hearing Scheduled for Tomorrowhttps://practicaldermatology.com/news/20120312-xeomin_injunction_stands_another_hearing_scheduled_for_tomorrow/2459848/Handing down his order as promised on Friday, US District Court Judge Andrew J. Guilford imposed a 10-month injunction barring Merz from selling or soliciting purchases of Xeomin®, in the US facial aesthetics market for 10 months. However, Judge Gui
- Cellceutix Files pre-IND Submission for Prurisol for Psoriasishttps://practicaldermatology.com/news/20120312-cellceutix_files_pre-ind_submission_for_prurisol_for_psoriasis/2459849/Cellceutix Corporation (OTCBB: CTIX) filed a pre-IND submission with the FDA for Prurisol (also termed KM-133), a drug in development for treatment of psoriasis. The company is seeking guidance to attain approval for a section 505(b)(2) designa
- Health plans sue Big Pharma over co-pay couponshttps://practicaldermatology.com/news/20120308-health_plans_sue_big_pharma_over_co-pay_coupons__read_more_health_plans_sue_big_pharma_over_co-pay_coupons_-_fiercepharma_httpwwwfiercepharmacomstoryh/2459850/Pharma's co-pay discounts have their fans--patients, certainly, and companies that have been able to boost prescriptions for high-priced drugs or hang onto sales as brands go off patent. But co-pay coupons and discount cards also have their detractors--namely, insurers and other payers trying to ste
- "Skin Rules" Hits Market March 13https://practicaldermatology.com/news/20120307-skin_rules_hits_market_march_13/2459854/Skin Rules (St. Martin's Press), a new book by dermatologist Debra Jaliman, MD, goes on sale March 13. According to a release, the book "lays out clear, easy-to-understand information on the latest technologies, such as Cool Sculpting (body co
- Sciton Expanding in Canadahttps://practicaldermatology.com/news/20120229-sciton_expanding_in_canada/2459860/Sciton, Inc., is establishing a direct presence in Canada. Noting a very strong and loyal customer base within Canada, the company says it views the Canadian market as an integral part of its corporate growth strategy. Sciton will expand its marketing, sales, clinical education and service offerings
- ARTAS System Receives Canadian Medical Device License to Treat Hair Losshttps://practicaldermatology.com/news/20120229-artas_system_receives_canadian_medical_device_license_to_treat_hair_loss/2459861/Restoration Robotics, Inc., a privately-held medical device company, today announced that its revolutionary ARTAS™ System has received a Canadian Medical Device License and can now be marketed and sold within Canada. The physician controlled ARTAS™ System allows them to quickly identify and harvest
- The Medical Entrepreneur Symposium Announces Sponsorshttps://practicaldermatology.com/news/20120229-the_medical_entrepreneur_symposium_announces_sponsors/2459863/The Medical Entrepreneur Symposium has finalized agreements with several initial sponsors for its upcoming educational seminar. Citrix GotoMeeting, AdvancedMD, Bernstein Wealth Management, Allergan Cosmetic, Obagi, Merz Aesthetics, and BTL Exilis have all agreed to sponsor the two-and-a-half-day sym
- ARTAS Medical System Coming to Texashttps://practicaldermatology.com/news/20120224-artas_medical_system_coming_to_texas/2459864/The ARTAS System, the first and only FDA cleared, physician controlled, computer assisted technology that allows harvesting individual follicular units directly from the scalp, is coming to Texas. <a href="www.markbisharamd.com" target="_blank">Mark A. Bishara, MD, PA,</a> a cosmetic sur
- New Rosacea Gel Coming Soonhttps://practicaldermatology.com/news/20120202-new_rosacea_gel_coming_soon/2459871/SkinCeuticals will soon unveil its Redness Neutralizer, a lightweight gel cream that prevents redness by targeting environmental triggers of inflammation leading to the onset of rosacea. Formulated wi
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe pl